Sai Parenterals Limited has announced a big win for its Australian subsidiary, Noumed Pharmaceuticals Pty Ltd. Noumed has renewed its exclusive OTC (over-the-counter) medicines supply agreement with one of Australia’s largest pharmacy chains.
The new deal is valued at AUD 202 million — around INR 1,300 crore (at 1 AUD = INR 64.5). It runs for 7.5 years, with an option to extend by another 3 years.
Deal at a Glance
- Deal value: AUD 202 million (~INR 1,300 crore)
- Annual value: About AUD 27 million per year
- Duration: 7.5 years, extendable to over 10 years
- New products added: 12 every year
- Effective from: July 1, 2026
This renewal comes with a bigger product list, a longer contract term, and a higher deal value than before — a sign of growing trust between Noumed and its Australian partner.
What Noumed Will Handle
Under the agreement, Noumed continues to manage the entire supply chain for these OTC products in Australia, including:
- Manufacturing
- Product sourcing
- Regulatory compliance and TGA registrations
- Warehousing and quality checks
- Nationwide distribution
This makes Noumed a one-stop, trusted partner for Australia’s pharmacy networks.
Why This Deal Matters for Sai Parenterals
For the Hyderabad-based parent company, this renewal brings several long-term benefits:
- Predictable revenue for years to come
- Stronger presence in the Australian OTC market
- Better use of existing manufacturing and regulatory setup
- More credibility as a trusted global pharma partner
- A launchpad for expansion into other regulated markets
What the Leadership Said
Mr. Anil Kumar Karusala, Managing Director, Sai Parenterals Limited, said the renewal reflects the confidence Australian pharmacy groups place in Noumed. He added that the deal supports future product launches and creates long-term value for the company and its stakeholders.
Mr. Mark Thulborne, CEO, Noumed Pharmaceuticals, said the long tenure of the deal shows the company’s ability to build lasting customer relationships and deliver quality products on time. He called it proof of Noumed’s growing role as a reliable partner in one of the world’s most tightly regulated pharma markets.
About Sai Parenterals
Founded in 2001, Sai Parenterals Limited is a global, IP-led pharmaceutical company with operations in India and Australia. It manufactures injectables and oral dosage products in India and is setting up a new oral dosage facility in Australia. The company serves customers across India and several regulated and semi-regulated international markets.
For more updates, visit www.saiparenterals.com.
){kind=link}